Sun Pharma, Dr Reddy's Labs, Aurobindo recall products in US over manufacturing issues

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2024-05-20 07:20 GMT | Update On 2024-05-20 07:20 GMT

New Delhi: According to the latest Enforcement Report from the US Food and Drug Administration (USFDA), pharmaceutical companies Dr Reddy's Laboratories, Sun Pharma, and Aurobindo Pharma are recalling products from the US market over manufacturing issues.

Dr Reddy's Laboratories is recalling close to 20,000 cartons of a medication used to control blood phenylalanine levels in adults and children.

Princeton (New Jersey) based Dr Reddy's Laboratories, Inc, is recalling Javygtor (sapropterin dihydrochloride) Powder for Oral Solution (100mg) due to it being a "Sub-potent Drug", USFDA stated.

The company is also recalling another lot of sapropterin dihydrochloride for the same reason, it added. The USFDA said the drug maker initiated the Class I recall in the US on April 8 this year.

As per the US health regulator, a Class I recall pertains to defective products that can cause serious health problems.

The USFDA said Sun Pharma is recalling 11,016 vials of Amphotericin B Liposome for Injection, used to treat fungal infections, in the US market.

The company's US-based arm initiated the Class II recall on April 19 this year due to "Out of specification for assay", the USFDA stated.

Similarly, "Aurobindo Pharma is recalling 13,605 bottles of Clorazepate Dipotassium Tablets (3.75 mg and 7.5 mg), used to treat anxiety, in the American market. The company's US-based arm is recalling the affected lot due to "Discoloration: Dotted and yellow spots on tablets", USFDA stated.

The company initiated the Class II recall on April 24 this year.

The USFDA stated that another drug firm FDC Ltd is recalling 3,82,104 units of Timolol Maleate Ophthalmic Solution, used to treat glaucoma, in the American market.

The Aurangabad (Maharashtra)-based drug firm is recalling the affected lot due to "Defective Container".

As per the USFDA, a Class II recall is initiated in a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.

The US generic drug market, estimated to be around USD 115.2 billion in 2019, is the largest market for pharmaceutical products.

Article Source : with inputs

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Sun Pharma, Dr Reddy's Labs, Aurobindo recall products in US over manufacturing issues

Similar News

USFDA approves expanded indication for Takeda Vonvendi for adults, children with Von Willebrand Disease

Roche receives EU CE mark for Contivue for neovascular age-related macular degeneration

SC Questions Effectiveness of UCPMP, Seeks Govt Clarification on Pharma Freebies

Dr Reddy's Labs API Mirfield facility gets 7 USFDA observations

CDSCO Panel Rejects Theon Pharma's Proposal for Empagliflozin, Linagliptin, Metformin FDC

Virchow Biotech Gets CDSCO Panel Nod for Semaglutide BE, Phase III Trials

Industry needs to come forward, take advantage of funds available for MedTech Sector: DoP Joint Secretary

USFDA inspection: Aurobindo Pharma receives 8 observations for Unit-XII